8-K
filed June 2, 2026, 4:01 PM ET
ticker FBRX
CIK 0001419041
other material
confidence high
sentiment neutral
materiality 0.40
Forte Biosciences stockholders approve amended equity plan adding 1.85M new shares
Forte Biosciences, Inc.
- Approved A&R 2021 Equity Incentive Plan with 1,850,000 newly requested shares; total reserve 5,190,000.
- Class III directors elected: Steven Kornfeld, Scott Brun, Paul A. Wagner (vote results provided).
- Advisory vote on named executive officer compensation for FY2025 passed (12.1M for, 3.8M against, 1.5M broker non-votes).
- KPMG ratified as independent auditor for FY2026 (17.7M for, 3K against, 40K abstentions).
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Forte Biosciences, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-29 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
2. Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 17,722,893 3,182 39,959 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Forte Biosciences, Inc. shareholders approved Approval of the Amended and Restated 2021 Equity Incentive Plan at the 2026-05-29 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
4. Approval of the Amended and Restated 2021 Equity Incentive Plan . The Company’s stockholders approved the A&R 2021 Equity Incentive Plan. The votes regarding the proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 11,911,879 3,997,050 351,042 1,506,063
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Forte Biosciences, Inc. shareholders approved Election of Class III Directors at the 2026-05-29 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
1. Election of Class III Directors. The following nominees were elected to serve as Class III directors, each to hold office until the Company’s 2029 annual meeting of stockholders or until his respective successor has been duly elected and qualified or his or her earlier resignation or removal: Nominee Votes For Votes Withheld Broker Non-Votes Steven Kornfeld 12,286,043 3,973,928 1,506,063 Scott Brun, M.D. 12,958,889 3,301,082 1,506,063 Paul A. Wagner, Ph.D. 16,027,110 232,861 1,506,063
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Forte Biosciences, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-05-29 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
3. Advisory Vote on Executive Compensation. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2025. The votes regarding the proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 12,143,153 3,764,729 352,089 1,506,063
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.